Home  /  Resource Library  /  The PI3K inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

The PI3K inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

Results of a study examining zandelisib for treatment of relapsed follicular lymphoma.